Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTavistock Regulatory News (TAVI)

Share Price Information for Tavistock (TAVI)

Share Price is delayed by 15 minutes
Get Live Data
3.15    0.00 (0.00%)
Bid:
3.00
Ask:
3.30
Spread: 0.30 (10.00%)
Market Cap: £13.89m
TAVI Live PriceLast checked at - London Stock Exchange

Intraday Tavistock Share Chart

Update re ongoing litigation

2 Oct 2025 07:00

RNS Number : 6833B
Tavistock Investments PLC
02 October 2025
 

Tavistock Investments Plc

("Tavistock" or the "Company")

 

 

2 October 2025

 

 

Tavistock Reasserts Commitment to Shareholders in Titan Legal Dispute

 

 

Further to the disclosures made in the Company's financial statements for the year ended 31 March 2025, Tavistock today provides an update on the ongoing litigation with Titan Wealth Services Limited and Titan Asset Management Limited ("Titan").

 

In June 2021, Tavistock announced its entry into a 10-year strategic partnership with Titan Wealth Services Limited. As a part of the arrangements Titan acquired Tavistock's asset management business and range of risk rated UCITS sub-funds, branded ACUMEN. It was also offered the opportunity to acquire Tavistock's Model Portfolio Service ("MPS") but declined to do so.

 

Less than one year into the partnership, Tavistock began to uncover multiple breaches by Titan of the strategic partnership agreement and earnout arrangements. In the opinion of Tavistock's Board, Titan's failure to honour the undertakings that it gave regarding the management of the acquired business led to a collapse in the performance of the ACUMEN Funds.

 

In order to protect the interests of the Company's shareholders, in 2024, Tavistock put Titan on notice of its intention to issue legal proceedings seeking damages. In response Titan, issued a claim in the High Court against the Company on a peremptory basis. Tavistock refuted this claim in the strongest terms and issued its own counterclaim seeking damages for multiple breaches of contract, including failures relating to the management of the ACUMEN fund range and the misuse of confidential information.

 

In June 2025 Tavistock made an application to expand the scope of its counterclaim against Titan to include new causes of action in respect of Titan's MPS for breach of confidence, alleged misuse of trade secrets and copyright infringement, and to add Titan Wealth Holdings Limited as an additional party. 

 

Titan opposes the expansion of the scope of Tavistock's counterclaim and has applied at the same time to strike out parts of the counterclaims.

 

A Court hearing has now been listed for December 2025 to determine both parties' applications. The Board remains confident in the strength of its case and continues to defend Titan's claim and pursue its own counterclaims vigorously.

 

Tavistock has offered Titan the opportunity to resolve the dispute via mediation. To date, this offer has been rejected. Unless Titan's approach changes, Tavistock will continue to pursue its claims through the courts.

 

Brian Raven, Tavistock's Chief Executive, commented:

 

"This litigation is not just about damages - it is about accountability. The evidence is clear that Titan's conduct caused reputational and financial harm, and we will not allow our shareholders to bear the cost of its mismanagement."

 

ACUMEN Fund Performance Under Titan's Management

 

Between 27 August 2022 and 4 January 2024 (after Tavistock began to uncover multiple breaches of contract), while under Titan's management, the ACUMEN fund suite experienced a dramatic collapse in performance. In all cases, the funds ranked in the bottom quartile of their respective peer groups for that 16-month period, in the 99th or 100th percentile.

 

 

 

  

Performance post Titan's breaches of contract

(27th Aug 2022 - 4th Jan 2024)

Performance vs Benchmark

Quartile Rank

Fund Rank

Percentile Rank

ACUMEN Portfolio 4

-7.89%

4th

176/177

100th

ACUMEN Portfolio 5

-8.27%

4th

177/177

100th

ACUMEN Portfolio 6

-9.72%

4th

212/215

99th

ACUMEN Portfolio 7

-11.19%

4th

214/215

100th

ACUMEN Portfolio 8

-13.51%

4th

157/159

99th

Average

-10.12%

4th

100th

Source of data: FE Analytics

 

The Company continues to manage the litigation process efficiently and separately from its operational and strategic priorities, which remain unaffected. Adverse costs insurance is also in place.

 

ENDS

 

 

For further information:

 

Tavistock Investments Plc

Oliver Cooke

Brian Raven

 

Tel: 01753 867000

Allenby Capital Limited

(Nominated adviser and broker)

Corporate Finance:

Nick Naylor, Daniel Dearden-Williams

Sales and Corporate Broking:

Tony Quirke

 

 

Tel: 020 3328 5656

Flagstaff Communications

(Financial PR/IR)

Tim Thompson

Alison Allfrey

Anna Probert

tavistock@flagstaffcomms.com

Tel: 0207 129 1474

 

Infinite

(Litigation PR)

Ryan McSharry

Matthew Gilleard

 

 

Tel: 0207 269 1430

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDUPGGAUUPAGWG
Date   Source Headline
13th Nov 200612:57 pmRNSHolding(s) in Company
13th Nov 200612:37 pmRNSResult of EGM
19th Oct 20067:01 amRNSIssue of Equity
21st Sep 20067:00 amRNSGrant of Options
15th Sep 20067:00 amRNSHolding(s) in Company
14th Sep 20067:00 amRNSHolding(s) in Company
11th Sep 200610:29 amRNSHolding(s) in Company
8th Sep 20061:15 pmRNSLicensing Agreement
8th Sep 20061:15 pmRNSDirector Resignation
7th Sep 200610:12 amRNSStmnt re Share Price Movement
27th Jul 20065:33 pmRNSAGM Statement
26th Jul 20062:42 pmRNSHolding(s) in Company
17th Jul 20062:36 pmRNSHolding(s) in Company
13th Jul 20063:37 pmRNSHolding(s) in Company
30th Jun 20067:02 amRNSFinal Results
14th Mar 20062:58 pmRNSHolding(s) in Company
9th Mar 20063:19 pmRNSHolding(s) in Company
30th Jan 20063:57 pmRNSHolding(s) in Company
12th Jan 20067:00 amRNSTrading Statement
7th Dec 20055:12 pmRNSStatement re share price move
15th Nov 20057:12 amRNSInterim Results
7th Nov 20059:43 amRNSHolding(s) in Company
7th Nov 20057:20 amRNSTrading Statement
13th Oct 200512:03 pmRNSExercise of Option
6th Oct 20057:00 amRNSStatement re Notice of Patent
14th Sep 20057:00 amRNSTrading Update
5th Aug 20054:31 pmRNSGrant of Options
5th Aug 20054:30 pmRNSFirst Shipment of Bubble
3rd Aug 20055:22 pmRNSAGM Statement
29th Jun 20057:01 amRNSAcquisition
29th Jun 20057:01 amRNSFinal Results
12th May 20054:34 pmRNSHolding(s) in Company
29th Apr 20055:11 pmRNSHolding(s) in Company
27th Apr 20059:49 amRNSHolding(s) in Company
11th Apr 20052:18 pmRNSHolding(s) in Company
6th Apr 20054:02 pmRNSHolding(s) in Company
1st Apr 200511:11 amRNSHolding(s) in Company
31st Mar 20056:11 pmRNSHolding(s) in Company
30th Mar 20053:58 pmRNSHolding(s) in Company
24th Mar 200511:32 amRNSResult of EGM
9th Mar 20055:19 pmRNSExercise of Option
2nd Mar 20057:01 amRNSPlacing and notice of EGM
23rd Feb 200511:42 amRNSPotential Fundraising
24th Jan 20057:18 amRNSUK distribution agreement
21st Jan 20055:06 pmRNSContent Agreement with HIT
17th Jan 200511:11 amRNSStmnt re Share Price Movement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.